Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
Princeton BioMeditech is a leading innovator and manufacturer of simple and rapid diagnostic products used at the point of care. The company offers more than 70 tests covering fertility management, infectious diseases, cardiac markers, drugs of abuse, cancer markers, environmental and veterinary diagnostics that enable consumers and professionals to improve speed and quality of diagnosis for better patient care.
Review of R&D system a highlight of the 2024–25 Budget
Australia's science bodies have been broadly positive about the 2024–25 federal Budget...
ACRF funds three new cancer research facilities
Scientists at QIMR Berghofer, the Peter MacCallum Cancer Centre and the Bio21 Institute have...
Govt announces $1.89bn package for health and medical research
The Australian Government is investing in a "once-in-a-generation transformation of health...
